Vivani Medical (VANI) Stock Price, News & Analysis

Company Overview

Vivani Medical Solutions, Inc. (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity. These products aim to reduce complications associated with percutaneous biopsies while facilitating efficient sample collection and handling, helping clinicians deliver faster and more accurate diagnoses.

Vivani Medical serves a broad customer base that encompasses hospitals, outpatient imaging centers and pathology service providers across the United States. In addition to its direct‐sales model, the company has established distribution partnerships to extend its reach into select European and Latin American markets, supporting growing international adoption of its technologies.

Founded in 2016 and headquartered in the United States, Vivani Medical became a publicly traded company in mid-2021, listing its common stock on the Nasdaq Capital Market under the ticker symbol “VANI.” The company’s leadership team brings together experienced professionals in medical device innovation, regulatory affairs and commercial operations, driving ongoing efforts to expand its product pipeline and reinforce its position in the interventional radiology market.

Key Stats

• Today's Range: $1.17 to $1.23
• 50-Day Range: $1.05 to $1.51
• 52-Week Range: $0.92 to $1.92
• Volume: 121,929 shs
• Average Volume: 272,454 shs
• Market Capitalization: $101.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Hold

Vivani Medical Stock Analysis - MarketRank™

Vivani Medical scored higher than 80% of companies evaluated by MarketBeat, and ranked 125th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Vivani Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vivani Medical has a consensus price target of $3.75, representing about 208.6% upside from its current price of $1.22.

Amount of Analyst Coverage

Vivani Medical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivani Medical is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivani Medical is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivani Medical has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.83% of the float of Vivani Medical has been sold short.

Short Interest Ratio / Days to Cover

Vivani Medical has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivani Medical has recently decreased by 14.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivani Medical does not currently pay a dividend.

Dividend Growth

Vivani Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.96

News Sentiment

Vivani Medical has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vivani Medical this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for VANI on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $5,999,998.00 in company stock, which represents 5.7262% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Vivani Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,999,998.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

53.30% of the stock of Vivani Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

6.78% of the stock of Vivani Medical is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/24/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VANI
• CIK: 1266806
• Web: www.vivani.com
• Phone: (818) 833-5000
• Fax: 818-833-5067
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vivani Medical: $3.75
• High Price Target: $4.00
• Low Price Target: $3.50
• Potential Upside/Downside: +216.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -264.04%
• Return on Assets: -79.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.18
• Quick Ratio: 3.18

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 5.93

Miscellaneous

• Outstanding Shares: 86,235,000
• Free Float: 40,272,000
• Market Cap: $102.27 million
• Optionable: Optionable
• Beta: 2.31